Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

REGN Regeneron Pharmaceuticals

Post-Mkt 08-06 18:10:52 EDT

772.11

+3.53

+0.46%

盘后772.11

+0.000.00%

18:06 EDT

High780.95	Low762.79	Vol783.95K
Open777.85	D1 Closing768.58	Amplitude2.36%
Mkt Cap79.49B	Tradable Cap76.35B	Total Shares102.95M
T/O603.44M	T/O Rate0.79%	Tradable Shares98.88M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"Regeneron Pharmaceuticals","latestPrice":772.11,"timestamp":1786046400000,"preClose":768.58,"halted":0,"volume":783945,"hourTrading":{"tag":"盘后","latestPrice":772.11,"preClose":772.11,"latestTime":"18:06 EDT","volume":354476,"amount":273680937.55583996,"timestamp":1786053995226,"change":0,"changeRate":0,"amplitude":0.005323},"delay":0,"changeRate":0.004592885581201661,"floatShares":98883600,"shares":102954988,"eps":40.43335,"marketStatus":"Post-Mkt","change":3.53,"latestTime":"08-06 18:10:52 EDT","open":777.85,"high":780.95,"low":762.785,"amount":603441373.69035,"amplitude":0.023634,"askPrice":774.35,"askSize":50,"bidPrice":763.2,"bidSize":1,"shortable":3,"etf":0,"ttmEps":40.43335,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1786060800000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":768.58,"dividendRate":0.004714,"preHourTrading":{"tag":"盘前","latestPrice":777.38,"preClose":768.58,"latestTime":"09:29 EDT","volume":3091,"amount":2378196.854,"timestamp":1786022999999,"change":8.8,"changeRate":0.01145,"amplitude":0.037427},"postHourTrading":{"tag":"盘后","latestPrice":772.11,"preClose":772.11,"latestTime":"18:06 EDT","volume":354476,"amount":273680937.55583996,"timestamp":1786053995226,"change":0,"changeRate":0,"amplitude":0.005323},"volumeRatio":0.814567,"impliedVol":0.2976,"impliedVolPercentile":0.0717},"requestUrl":"/m/hq/s/REGN","defaultTab":"news","newsList":[{"id":"2657665459","title":"Regeneron Posts Transcript of Q2 2026 Earnings Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2657665459","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657665459?lang=en_us&edition=fundamental","pubTime":"2026-08-07 02:48","pubTimestamp":1786042119,"startTime":"0","endTime":"0","summary":"Regeneron posts transcript of Q2 2026 earnings conference callRegeneron’s Q2 2026 earnings call drew CEO Leonard Schleifer, CSO George Yancopoulos, Commercial EVP Marion McCourt, CFO Christopher Fenimore.Revenue rose 17% to USD 4.3 billion; non-GAAP EPS increased 11% to USD 14.29, including a USD 0.99 hit from acquired IPR&D charges.EYLEA HD U.S. net sales reached USD 596 million, up 52%; management targeted EYLEA HD prefilled-syringe clearance before year-end using more than two CMOs.Sanofi collaboration revenue hit USD 2.2 billion; Fenimore flagged a step-up starting Q3 as the USD 3.1 billion Sanofi development balance was fully repaid.Management guided to August FDA action for garetosmab in FOP; November FDA decision for cemdisiran in gMG; PNH registrational readout in Q4.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL67NH1y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250504.SGD","LU2089984988.USD","IBB","BK4588","REGN","BK4139","LU2362541513.USD","LU0889565916.HKD","LU1974910355.USD","LU0289739699.SGD","LU0320765992.SGD","LU2106854487.HKD","LU0823434583.USD","LU0114720955.EUR","LU2468319806.SGD","LU2237438978.USD","LU0053666078.USD","BBH","LU2362540622.SGD","LU0058720904.USD","IBBQ","LU0882574055.USD","BK4585","LU2362541273.HKD","TBXU","LU0823416689.USD","LU1917777945.USD","LU0823434740.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657739653","title":"Regeneron Canada Says Libtayo Receives Health Canada Approval for Treatment of a Type of Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2657739653","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657739653?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:43","pubTimestamp":1786031036,"startTime":"0","endTime":"0","summary":"Aug 6 (Reuters) - Regeneron Canada::*REGENERON CANADA: LIBTAYO RECEIVES HEALTH CANADA APPROVAL FOR ADJUVANT TREATMENT OF HIGH-RISK CUTANEOUS SQUAMOUS CELL CARCINOMA((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 06-AUG-202615:30:00.257 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nRSD2CjPQd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2106854487.HKD","IBB","LU0823434583.USD","IBBQ","LU0058720904.USD","LU0823416689.USD","LU0889565916.HKD","LU2023250504.SGD","BK4588","BK4585","LU0823434740.USD","LU2362540622.SGD","LU1974910355.USD","LU2089984988.USD","LU0053666078.USD","LU2362541273.HKD","REGN","LU0320765992.SGD","LU0882574055.USD","TBXU","LU2362541513.USD","BK4139","LU0109394709.USD","LU2237438978.USD","LU1917777945.USD","BBH","LU0289739699.SGD","LU0114720955.EUR","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657653754","title":"Regeneron announces Health Canada approval of new indication for Libtayo","url":"https://stock-news.laohu8.com/highlight/detail?id=2657653754","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657653754?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:35","pubTimestamp":1786030528,"startTime":"0","endTime":"0","summary":"Regeneron (REGN) Canada announced that Health Canada has issued a Notice of Compliance for Libtayo for the adjuvant treatment of adult patients wit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regeneron-announces-health-canada-approval-of-new-indication-for-libtayo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regeneron-announces-health-canada-approval-of-new-indication-for-libtayo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBH","LU2237438978.USD","LU0889565916.HKD","BK4588","LU1974910355.USD","LU2106854487.HKD","LU0823434583.USD","LU0289739699.SGD","LU0109394709.USD","LU0053666078.USD","LU1917777945.USD","LU0320765992.SGD","LU2089984988.USD","REGN","TBXU","BK4585","LU2362541273.HKD","LU0823434740.USD","LU2468319806.SGD","LU0882574055.USD","LU2362541513.USD","IBBQ","LU0114720955.EUR","LU2023250504.SGD","LU0823416689.USD","LU0058720904.USD","IBB","BK4139","LU2362540622.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657653183","title":"Regeneron Canada: Libtayo Receives Health Canada Approval for Adjuvant Treatment of High-Risk Cutaneous Squamous Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2657653183","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657653183?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:30","pubTimestamp":1786030236,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN4431G9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0882574055.USD","LU1974910355.USD","LU2089984988.USD","LU0289739699.SGD","LU0109394709.USD","LU2237438978.USD","LU0889565916.HKD","LU0058720904.USD","LU0114720955.EUR","LU2362540622.SGD","TBXU","IBB","LU0823434583.USD","LU0823416689.USD","LU2023250504.SGD","LU2362541273.HKD","BK4588","LU2362541513.USD","BBH","LU0320765992.SGD","BK4139","LU0823434740.USD","BK4585","IBBQ","LU0053666078.USD","LU1917777945.USD","REGN","LU2106854487.HKD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657560633","title":"Intellia Therapeutics Q2 Collaboration Revenue Falls, Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2657560633","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657560633?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:20","pubTimestamp":1786015252,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Q2 collaboration revenue falls, net loss widensOverviewU.S. gene editing firm's Q2 collaboration revenue fell yr/yr due to lower Regeneron revenueQ2 net loss widened from prior y","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430JC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","LU1861559042.SGD","LU0109394709.USD","LU0114720955.EUR","IBBQ","BK4556","LU0882574055.USD","LU0823416689.USD","ARKG","LU2362540622.SGD","LU0823434740.USD","LU0320765992.SGD","LU1974910355.USD","LU0053666078.USD","LU1917777945.USD","LU2023250504.SGD","LU0823434583.USD","LU2468319806.SGD","LU2237438978.USD","REGN","LU1861558580.USD","CRSP","LU0889565916.HKD","BK4611","PGEN","LU2362541273.HKD","BBH","BK4588","LU2362541513.USD","IBB","LU0058720904.USD","LU2089984988.USD","EDIT","TBXU","BK4585","LU0289739699.SGD","LU2106854487.HKD","NTLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638109","title":"Intellia Q2 FY26 Net Loss Widens to $106.63 Million; Revenue Falls to $7.66 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638109","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638109?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:09","pubTimestamp":1786014575,"startTime":"0","endTime":"0","summary":"Intellia Q2 FY26 net loss widens to $106.63 million; revenue falls to $7.66 millionIntellia posted a GAAP net loss of USD 106.63 million, widening from USD 101.26 million a year earlier; loss per shar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL3QMBnk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861559042.SGD","LU0823434583.USD","LU2362541513.USD","BK4139","LU2362541273.HKD","LU0823434740.USD","BK4556","LU0320765992.SGD","LU0114720955.EUR","LU0889565916.HKD","LU1974910355.USD","LU1861558580.USD","LU2106854487.HKD","LU2362540622.SGD","IBB","LU2237438978.USD","LU0058720904.USD","BBH","IBBQ","BK4585","LU2023250504.SGD","LU0882574055.USD","NTLA","REGN","LU0289739699.SGD","LU2468319806.SGD","LU0823416689.USD","TBXU","LU0053666078.USD","LU2089984988.USD","BK4588","LU1917777945.USD","LU0109394709.USD","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657636575","title":"Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared to Competitors Despite Daily Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2657636575","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657636575?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:45","pubTimestamp":1785962700,"startTime":"0","endTime":"0","summary":"DJ Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors Despite Daily GainsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  rose 1.04% to $768.58 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average  rising 0.49% to 54,349.12 and the S&P 500 Index  falling 0.17% to 7,723.55.This was the stock's second consecutive day of gains.Regeneron Pharmaceuticals Inc. closed 6.40% below its 52-week high of $821.11, which the company reached on January 9th.The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Amgen Inc.  rose 4.57% to $407.83, Moderna Inc.  fell 1.29% to $56.26, and Gilead Sciences Inc.  fell 2.58% to $131.76.Trading volume  remained 465,545 below its 50-day average volume of 995,354.Data source: Dow Jones Market Data, FactSet. Data compile","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657954823","title":"Wall Street Warms to Healthcare Stocks as Tech Trade Faces Turbulence","url":"https://stock-news.laohu8.com/highlight/detail?id=2657954823","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657954823?lang=en_us&edition=fundamental","pubTime":"2026-08-05 22:45","pubTimestamp":1785941112,"startTime":"0","endTime":"0","summary":"Healthcare funds saw $2.44 bln in inflows in July.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL4N4400DW:1","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Wall Street Warms to Healthcare Stocks as Tech Trade Faces Turbulence","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0162691827.USD","LU0310800379.SGD","LU0124676726.USD","LU2357305700.SGD","LU0096364046.USD","BK4534","LU0048584097.USD","LU1989771016.USD","LU1064131342.USD","LU0225771236.USD","LU0689472784.USD","LU2087621335.USD","SGXZ51526630.SGD","IYH","SG9999014914.USD","LU0098860793.USD","LU0861579265.USD","LU0057025933.USD","LU0353189763.USD","LU2129689605.HKD","PJP","SG9999011175.SGD","LU1496350171.SGD","LU0316494557.USD","LU1119994496.HKD","AMGN","LU0882574055.USD","ABBV","LU0211328371.USD","LU2237443382.USD","LLII","IE000M9KFDE8.USD","LU1670711040.USD","NVOH","BK4559","LU0203345920.USD","LU0949170772.SGD","LU2125909247.SGD","LU0211327993.USD","LU2462591277.SGD","LU0354030438.USD","LU0094547139.USD","LU0198837287.USD","LU1037948541.HKD","LU1670627923.USD","LU1674673428.USD","LU1814569148.SGD","LU2028103732.USD","IE00B19Z8W00.USD","LU0553294199.USD","LU0557290698.USD","RXL","IE00BFXG1179.USD","MEDX","LU0306806265.USD","LU1084165304.USD","LU1791710400.SGD","LU1548497426.USD","LU1066051811.HKD","LU2023251221.USD","IE0004445239.USD","LU0107464264.USD","LU2361044949.HKD","LU0256863902.USD","LU0859254822.USD","LU2491049909.HKD","LU2491050071.SGD","LU0965509101.SGD","LU1551013425.SGD","LU2244417387.USD","LU1244550221.USD","LU1023059063.AUD","LU0985481810.HKD","SG9999018865.SGD","LU2242646821.SGD","ELIL","LU0029864427.USD","LU1066051498.USD","LU0545039389.USD","LU1854104046.USD","LU2552382058.USD","LU1854103824.USD","LU2087625088.SGD","IE00BBT3K403.USD","LU0143551892.USD","LU0868494708.USD","IE0005OL40V9.USD","LU1066053197.SGD","LU2237443549.SGD","IE00B3T34201.USD","LU0225284248.USD","LU1267930227.SGD","LU1868836757.USD","HRTS","LU0128525689.USD","BMY","UNH","JDOC","IE0004445015.USD","LU2954938101.SGD","LU0053666078.USD","SG9999001440.SGD","IE0002270589.USD","IE00BZ9MQY76.HKD","LU2999663052.SGD","LU0289961442.SGD","LU0432979614.USD","LU0528227936.USD","LU0187121727.USD","LU0052756011.USD","IE00B19Z8X17.USD","IE00B19Z9505.USD","LU2552382132.HKD","LU1989772923.USD","BK4566","LU1868837136.USD","LU0353189680.USD","SG9999017495.SGD","SG9999015978.USD","IE00BLSP4452.SGD","LU2362540622.SGD","IE0009355771.USD","SG9999018857.SGD","LU1720051017.SGD","LU1261432733.SGD","LLYX","IE00BN29S564.USD","LU2236285917.USD","LU2111349929.HKD","LU0787776722.HKD","LU0354030511.USD","FTXH","LU1934455277.USD","LU2125154935.USD","SGXZ81514606.USD","LU1003077747.HKD","IE00BN8TJ469.HKD","LU0965509010.AUD","SGXZ99366536.SGD","LU0234570918.USD","IE00B1BXHZ80.USD","BK4581","LU0320765992.SGD","LU0738911758.USD","LU1839511570.USD","LU2237443465.HKD","IE00B7KXQ091.USD","NVO","IE00B7SZLL34.SGD","LU0820561818.USD","LU0417517546.SGD","LU2089283258.USD","LU0058720904.USD","LU0985320562.USD","LU1153585028.USD","LU0511384066.AUD","IE00BDGV0183.EUR","LU1883839398.USD","LU0069063385.USD","LU0976567544.SGD","LU0689626769.HKD","SG9999015952.SGD","LU1670711123.USD","IE000F7OJYX1.SGD","LU1093756168.USD","LU1267930573.SGD","LU1829250122.USD","IE00BFSS7M15.SGD","LU1267930730.SGD","SG9999014906.USD","LU0310800965.SGD","LU0234572021.USD","SG9999015986.USD","SG9999002224.SGD","LU0965508806.USD","LU0267386448.USD","LU0345770308.USD","LU1670710661.SGD","IE00B4R5TH58.HKD","LU0310799852.SGD","LU2089284900.SGD","IE0000B7K699.USD","LU0170899867.USD","IE00BKVL7J92.USD","IHE","LU1032466523.USD","LU2596442595.SGD","BK4532","LU0238689110.USD","SG9999001176.SGD","LLY","LU1868836591.USD","LU1069347547.HKD","LU1778281490.HKD","LU0289739699.SGD","LU0708995401.HKD","LU2362541273.HKD","IE00BFSS8Q28.SGD","LU2417539215.USD","LU2361045086.USD","LU0889565916.HKD","LU2362541513.USD","LU1791710582.SGD","LU0289739343.SGD","IHF","SG9999013999.USD","IE00BKPKM429.USD","IE000BZT7R73.USD","IE00B2B36J28.USD","LU0251132253.USD","LU0306807586.USD","IE00BLSP4239.USD","LU1670710588.SGD","LU1720051108.HKD","LU0149725797.USD","LU2347655156.SGD","LU0109394709.USD","MRK","LU0266013472.USD","LU1585245621.USD","TRUH","IE00BVYPNV92.GBP","LU0203347892.USD","LU0943347566.SGD","LU2112291526.USD","SGXZ31699556.SGD","LU0320765059.SGD","LU0109391861.USD","BK4568","IE00BJJMRZ35.SGD","IE000SO60NU8.SGD","LU2324357040.USD","LU2433249047.HKD","UNHU","LU2279689827.SGD","SG9999014898.SGD","LU0158827948.USD","IE00B4JS1V06.HKD","IE00B894F039.SGD","IE00B19Z3581.USD","SG9999015945.SGD","LU2271345857.HKD","LU1934455863.HKD","LU1923622614.USD","UNHG","LU2129689431.USD","IE00B42XCP33.USD","LU0496365809.HKD","LU0823416689.USD","IE00BGHQF631.EUR","LU0345770993.USD","LLYZ","LU0158827781.USD","IE00BFTCPJ56.SGD","IE00BJJMRX11.SGD","LU2491050154.USD","LU1929549753.HKD","IE00B19Z3B42.SGD","LU1868837300.USD","LU0942090050.USD","LU1868836914.USD","LU0211326755.USD","IE00B775H168.HKD","LU1732799900.SGD","LU0912757837.SGD","LU1035773651.USD","LU0061475181.USD","LU2347655073.USD","LU1914381329.SGD","BK4533","BK4588","LU2357627491.SGD","PPH","IE00BSNM7G36.USD","LU1732800096.USD","SG9999014880.SGD","LU0097036916.USD","LU1244550577.SGD","LU2237443622.USD","LU0795875086.SGD","AGNG","LU1037948897.HKD","LU1066051225.USD","LU1061106388.HKD","LU1934455194.USD","LU2456880835.USD","LU1093756325.SGD","LU1323610961.USD","SGXZ57979304.SGD","LU0708994859.HKD","LU1496350502.SGD","LU2133065610.SGD","LU0342679015.USD","IXJ","LU2468319806.SGD","LU1670628061.USD","LU0456855351.SGD","SG9999001176.USD","XLV","LU0868494617.USD","LU0077335932.USD","LU0672654240.SGD","LU0128525929.USD","LU1074936037.SGD","LU2211815571.USD","BK4007","IE000WAW04H5.SGD","BK4154","IE000MB6IJN5.SGD","IE0002141913.USD","UNHW","FHLC","IE00B19Z9Z06.USD","IE00BJT1NW94.SGD","NVOX","IE00B1XK9C88.USD","IE00BWXC8680.SGD","LU0237698245.USD","LU2125154778.USD","LU0661504455.SGD","LU2361044865.SGD","LU2552382215.SGD","LU2125909593.SGD","BK4139","BK4585","VHT","LU2242649171.HKD","LU0321505868.SGD","LU2264538146.SGD","LU0011850046.USD","LU0211326839.USD","LU1244550494.USD","SG9999003800.SGD","LU0320765646.SGD","BK4550","LU2242652126.USD","GDOC","AZN","LU1430594728.SGD","LU0072461881.USD","LU0122379950.USD","LU1291159041.SGD","LU1674673691.USD","LU2089984988.USD","AZNH","LU0256863811.USD","IE00B19Z9P08.USD","LU1989772840.SGD","LU1551013342.USD","LU1571399168.USD","LU1267930490.SGD","LU2461242641.AUD","LU0726765562.USD","LU0079474960.USD","IE00BJJMRY28.SGD","LU2237443895.HKD","GLAM","LU2462157665.USD","LU0321505439.SGD","LU0683600562.USD","REGN","LU2237443978.SGD","LU0820562030.AUD","SG9999002232.USD","MHIP","LU1983299246.USD","LU1057294990.SGD","LU1162221912.USD","LU1506573853.SGD","IE00BVYPNW00.USD","LU2360032135.SGD","IE00B3PB1722.GBP","TMED","IE00BZ1G4Q59.USD","ELIS","LU0820561909.HKD","LU1988902786.USD","LU0114720955.EUR","LU0395794307.EUR","LU1718418525.SGD","LU0795875169.SGD","LU0472753341.HKD","LU2129689514.USD","LU0965509283.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657688885","title":"Does Regeneron (REGN) Prioritize Shareholder Returns Over Earnings Quality As Profit Slips Amid Rising Sales?","url":"https://stock-news.laohu8.com/highlight/detail?id=2657688885","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657688885?lang=en_us&edition=fundamental","pubTime":"2026-08-04 23:34","pubTimestamp":1785857668,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals, Inc. previously reported second-quarter 2026 revenue of US$4,290.7 million versus US$3,675.6 million a year earlier, while net income eased to US$1,296.9 million from US$1,391.6 million and diluted earnings per share from continuing operations slipped to US$12.23 from US$12.81.\nAt the same time, the company affirmed a quarterly dividend of US$0.94 per share payable on August 31, 2026, underscoring its willingness to return cash to shareholders even as earnings...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/does-regeneron-regn-prioritize-shareholder-returns-over-earn","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/does-regeneron-regn-prioritize-shareholder-returns-over-earn","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656853990","title":"Fujian Haixi Pharma Wins FDA IND Clearance for Hx9428 Phase II nAMD Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2656853990","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656853990?lang=en_us&edition=fundamental","pubTime":"2026-08-04 17:13","pubTimestamp":1785834780,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharma wins FDA IND clearance for HX9428 Phase II nAMD trialFujian Haixi Pharmaceuticals secured US FDA IND clearance to start a Phase II trial of oral nAMD candidate HX9428 in the US.Chi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL356fXN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","LU2106854487.HKD","LU0889565916.HKD","LU0320765992.SGD","LU0058720904.USD","BK1191","TBXU","REGN","LU2023250504.SGD","LU0109394709.USD","BK4585","LU2468319806.SGD","LU0823434583.USD","02637","LU2362541513.USD","BK4139","LU0289739699.SGD","LU0882574055.USD","IBBQ","LU2362541273.HKD","LU0823416689.USD","LU2237438978.USD","BK4588","LU0053666078.USD","LU1917777945.USD","BBH","LU2362540622.SGD","LU0823434740.USD","LU1974910355.USD","IBB","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656637795","title":"Regeneron Pharma is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2656637795","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656637795?lang=en_us&edition=fundamental","pubTime":"2026-08-03 22:32","pubTimestamp":1785767520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/REGN/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU0109394709.USD","LU2468319806.SGD","REGN","LU2089984988.USD","LU0289739699.SGD","LU0882574055.USD","LU2106854487.HKD","IBBQ","LU2362541513.USD","LU1974910355.USD","LU0114720955.EUR","LU0889565916.HKD","LU2362540622.SGD","BK4588","LU1917777945.USD","LU0320765992.SGD","BBH","LU2237438978.USD","BK4585","LU0053666078.USD","LU0823434740.USD","LU2023250504.SGD","IBB","LU0823416689.USD","BK4139","LU2362541273.HKD","TBXU","LU0823434583.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656737918","title":"Achieve Life Sciences Names Ronald Dadino SVP of CMC and Supply Chain","url":"https://stock-news.laohu8.com/highlight/detail?id=2656737918","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656737918?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:32","pubTimestamp":1785760322,"startTime":"0","endTime":"0","summary":"Achieve Life Sciences names Ronald Dadino SVP of CMC and supply chainAchieve Life Sciences named Ronald Dadino SVP of CMC and supply chain as it prepares a cytisinicline NDA resubmission.Dadino previo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL8dB3Lg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","GDOC","RXL","LU1674673691.USD","IE00BKVL7J92.USD","FHLC","LU1066051225.USD","MEDX","IHE","SG9999014005.SGD","IE00BJT1NW94.SGD","NDAQ","IBBQ","JDOC","MCRB","FTXH","IE00B3T34201.USD","IE00BN8TJ469.HKD","LU1732800096.USD","TRUH","LU0795875086.SGD","VHT","REGN","BCDF","LU0823434583.USD","LU2129689431.USD","ACHV","LU0345770993.USD","SG9999002224.SGD","JNJ","IE0009355771.USD","IE00BN0W2W23.USD","IBB","BBH","LU0683600562.USD","LU2106854487.HKD","LU2403377893.USD","LU1261432733.SGD","LU1551013425.SGD","IYH","LU1267930813.SGD","LU1228905540.USD","PJP","XLV","BMED","TBXU","LU0210528500.USD","IXJ","IE00B2B36J28.USD","LU0640476718.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656376040","title":"Regeneron Pharmaceuticals (REGN) Posts Strong Q2 Revenue, Is The Upside Already Priced In?","url":"https://stock-news.laohu8.com/highlight/detail?id=2656376040","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656376040?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:16","pubTimestamp":1785755802,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) is back in focus after reporting second quarter 2026 results that showed revenue of US$4.29b, alongside a quarterly dividend declaration and a new radiopharmaceuticals collaboration with Telix Pharmaceuticals.\nSee our latest analysis for Regeneron Pharmaceuticals.\nAt a share price of US$762.63, Regeneron Pharmaceuticals has seen a 30 day share price return of 22.08% and a 1 year total shareholder return of 37.21%. This points to building momentum following...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-posts-strong-q2-revenue-is-th","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-posts-strong-q2-revenue-is-th","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656436378","title":"Regeneron price target raised to $740 from $700 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2656436378","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656436378?lang=en_us&edition=fundamental","pubTime":"2026-08-03 18:41","pubTimestamp":1785753705,"startTime":"0","endTime":"0","summary":"Citi raised the firm’s price target on Regeneron (REGN) to $740 from $700 and keeps a Neutral rating on the shares. The firm updated models in the ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regeneron-price-target-raised-to-740-from-700-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regeneron-price-target-raised-to-740-from-700-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2089984988.USD","BK4585","LU2106854487.HKD","LU0823434740.USD","LU2468319806.SGD","LU0882574055.USD","LU2237438978.USD","LU2362540622.SGD","TBXU","LU1917777945.USD","LU1974910355.USD","LU0289739699.SGD","IBB","IBBQ","LU2023250504.SGD","LU2362541513.USD","LU0889565916.HKD","LU2362541273.HKD","LU0114720955.EUR","LU0058720904.USD","LU0320765992.SGD","LU0823434583.USD","BBH","LU0053666078.USD","BK4588","LU0109394709.USD","BK4139","REGN","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656342208","title":"Biocon Launches Yesafili Biosimilar to Regeneron’s Eylea in US","url":"https://stock-news.laohu8.com/highlight/detail?id=2656342208","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656342208?lang=en_us&edition=fundamental","pubTime":"2026-08-03 11:34","pubTimestamp":1785728040,"startTime":"0","endTime":"0","summary":"Biocon launches Yesafili biosimilar to Regeneron’s Eylea in USBiocon Biologics launched Yesafili in the U.S., targeting a high-volume retinal disease market with an interchangeable biosimilar to Eylea","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL4Ww2Qc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541273.HKD","LU2468319806.SGD","TBXU","LU0109394709.USD","LU0320765992.SGD","LU0882574055.USD","LU2023250504.SGD","BK4139","BK4588","LU0823416689.USD","LU2362540622.SGD","LU0823434583.USD","LU2106854487.HKD","LU2089984988.USD","LU0289739699.SGD","BK4585","LU0889565916.HKD","LU0114720955.EUR","LU0058720904.USD","LU1917777945.USD","LU2362541513.USD","LU0053666078.USD","IBB","LU1974910355.USD","REGN","BBH","LU0823434740.USD","LU2237438978.USD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168493029","title":"Weekly Winners | Microsoft Rockets 22%; Garmin Soars 21%; Amazon, Chipotle Jump 17% Each; Regeneron Pharmaceuticals Gains 16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168493029","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168493029?lang=en_us&edition=fundamental","pubTime":"2026-08-02 13:58","pubTimestamp":1785650303,"startTime":"0","endTime":"0","summary":"This week, which stocks lagged or dragged? Weekly Winners column keeps up with market trends, helping Tigers sort out the week's hottest sectors, stock winners and important news.Below are top 10 S&P...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"330240692f324d079ccf839d9e4180bf","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSFX","CTSH","CMG","MSFL","AMZP","MSFD","MSFY","AMZU","MSFO","GRMN","CMGG","AMZW","DXCM","AZYY","AMZD","WDAY","BAX","MSFW","AMZZ","CHTR","AMZY","AMZN","MSFU","REGN","MSFT"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1117970979","title":"Movement Alert｜Regeneron Pharmaceuticals Rises 3.09% in Regular Trading, Q2 Earnings Beat Continues to Drive Stock Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=1117970979","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117970979?lang=en_us&edition=fundamental","pubTime":"2026-08-01 03:25","pubTimestamp":1785525922,"startTime":"0","endTime":"0","summary":"On August 1, Regeneron Pharmaceuticals rose 3.09% in regular trading, trading at approximately $761.18 per share, with turnover of $5.49 billion. The stock continued its upward momentum following a...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655609133","title":"Regeneron Announces Q3 2026 Distribution of R$ 0.05 Per Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2655609133","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655609133?lang=en_us&edition=fundamental","pubTime":"2026-07-31 23:27","pubTimestamp":1785511636,"startTime":"0","endTime":"0","summary":"Regeneron announces Q3 2026 distribution of R$ 0.05 per unitRegeneron announced a 3Q 2026 distribution of R$ 0.05 per unit (ISIN BRREGNBDR005).Last day to trade with entitlement: Aug. 14, 2026.Payment","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL8MHy3M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250504.SGD","BK4585","IBBQ","LU0823434583.USD","LU0889565916.HKD","BBH","LU0053666078.USD","LU0114720955.EUR","LU2106854487.HKD","LU0058720904.USD","LU0823434740.USD","LU0289739699.SGD","LU2362541273.HKD","LU0823416689.USD","LU0109394709.USD","LU2237438978.USD","LU2468319806.SGD","BK4588","LU1917777945.USD","LU1974910355.USD","LU2089984988.USD","LU2362541513.USD","LU0882574055.USD","LU2362540622.SGD","BK4139","IBB","REGN","TBXU","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655124360","title":"Regeneron Pharmaceuticals' Robust Q2 Sales Amid Limited Spend Increases to Help Ramp H2 Margins, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2655124360","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655124360?lang=en_us&edition=fundamental","pubTime":"2026-07-31 23:21","pubTimestamp":1785511282,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals'  robust Q2 sales from key products and limited spend increases are expected to help ramp H2 margins, RBC Capital Markets said in a Thursday research report.The company's collaboration with Sanofi  could become a \"more leverageable asset\" in advancing immunology and inflammation products if the companies continue to sound more communicative, analysts wrote.A decent uptake of Eylea HD to treat retinal conditions during the quarter is a clear positive for the company, analysts said, adding that they now model Eylea franchise US sales of $3.9 billion in 2026.The brokerage said it reiterated its sector perform rating on the stock and boosted its price target to $737 per share from $696.Price: 736.42, Change: -1.92, Percent Change: -0.26","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655361027","title":"Regeneron Pharma is Maintained at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2655361027","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655361027?lang=en_us&edition=fundamental","pubTime":"2026-07-31 21:37","pubTimestamp":1785505020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/REGN/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541513.USD","LU0058720904.USD","TBXU","LU0882574055.USD","BK4139","LU0053666078.USD","LU2362540622.SGD","IBBQ","LU0889565916.HKD","BK4585","LU2362541273.HKD","LU2237438978.USD","LU2023250504.SGD","LU2468319806.SGD","LU2089984988.USD","LU0109394709.USD","IBB","LU0320765992.SGD","LU0823416689.USD","LU0823434740.USD","LU1974910355.USD","LU0114720955.EUR","LU0823434583.USD","BBH","REGN","LU1917777945.USD","LU2106854487.HKD","BK4588","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":0.1052},{"period":"1month","weight":0.1828},{"period":"3month","weight":0.0839},{"period":"6month","weight":-0.0216},{"period":"1year","weight":0.3486},{"period":"ytd","weight":-0.0043}],"compareEarnings":[{"period":"1week","weight":0.0553},{"period":"1month","weight":0.0246},{"period":"3month","weight":0.0522},{"period":"6month","weight":0.1146},{"period":"1year","weight":0.2258},{"period":"ytd","weight":0.1289}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.514286,"avgChangeRate":0.03675},{"month":2,"riseRate":0.428571,"avgChangeRate":0.086855},{"month":3,"riseRate":0.457143,"avgChangeRate":-0.043382},{"month":4,"riseRate":0.457143,"avgChangeRate":0.014275},{"month":5,"riseRate":0.611111,"avgChangeRate":0.052257},{"month":6,"riseRate":0.444444,"avgChangeRate":0.006953},{"month":7,"riseRate":0.666667,"avgChangeRate":0.057379},{"month":8,"riseRate":0.555556,"avgChangeRate":0.022458},{"month":9,"riseRate":0.457143,"avgChangeRate":0.023281},{"month":10,"riseRate":0.4,"avgChangeRate":-0.00141},{"month":11,"riseRate":0.542857,"avgChangeRate":0.046018},{"month":12,"riseRate":0.485714,"avgChangeRate":0.043803}],"exchange":"NASDAQ","name":"Regeneron Pharmaceuticals","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Regeneron Pharmaceuticals,REGN,Regeneron Pharmaceuticals股票,Regeneron Pharmaceuticals股票老虎,Regeneron Pharmaceuticals股票老虎国际,Regeneron Pharmaceuticals行情,Regeneron Pharmaceuticals股票行情,Regeneron Pharmaceuticals股价,Regeneron Pharmaceuticals股市,Regeneron Pharmaceuticals股票价格,Regeneron Pharmaceuticals股票交易,Regeneron Pharmaceuticals股票购买,Regeneron Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}